sign in sign up
<<
Home , Ajanta Pharma, Apollo Hospitals, Fortis Healthcare, Ipca Laboratories

Modera erate tely Mod High to e H w at ig o er h L d o M V e r y w H Tata Pharma & Healthcare Fund o i L g (An open ended equity scheme investing in Pharma and Healthcare Services Sector) h Riskometer Investors understand that their principal As on 30th June 2021 PORTFOLIO will be at Very High Risk

INVESTMENT STYLE Company name No. of Market Value % of Company name No. of Market Value % of Primarily focuses on investment in at least 80% of its net Shares Rs. Lakhs Assets Shares Rs. Lakhs Assets assets in equity/equity related instruments of the companies in the Pharma & Healthcare sectors in India. Equity & Equity Related Total 55184.24 97.88 Ltd. 167000 1089.76 1.93 INVESTMENT OBJECTIVE Healthcare Services India Ltd. 13000 997.39 1.77 The investment objective of the scheme is to seek long Apollo Enterprise Ltd. 70500 2551.99 4.53 Gland Pharma Ltd. 19662 673.29 1.19 term capital appreciation by investing atleast 80% of its Ltd. 795000 1935.03 3.43 Laurus Labs Ltd. 90000 619.79 1.10 net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in Syngene International Ltd. 265000 1545.75 2.74 India.However, there is no assurance or guarantee that the investment objective of the Scheme will be Narayana Hrudayalaya Ltd. 301420 1483.74 2.63 Other Equities^ 1186.14 2.10 achieved.The Scheme does not assure or guarantee any Metropolis Healthcare Ltd. 43000 1219.37 2.16 returns. Repo 1396.26 2.48 Krishna Institute Of Medical Sciences Ltd. 116982 1107.88 1.97 DATE OF ALLOTMENT Portfolio Total 56580.50 100.40 Dr. Lal Path Labs Ltd. 29000 949.01 1.68 December 28, 2015 Net Current Liabilities -226.44 -0.40 Healthcare Global Enterprises Ltd. 410000 918.40 1.63 FUND MANAGER Pharmaceuticals Net Assets 56354.06 100.00 Meeta Shetty (Managing Since 09-Mar-21 and overall experience of 14 years) Sun Pharmaceutical Industries Ltd. 790100 5336.73 9.47 ^ Exposure less than 1% has been clubbed under Other Equities Dr Reddys Laboratories Ltd. 96000 5206.13 9.24 BENCHMARK Ltd. 500000 4859.50 8.62 Nifty Pharma TRI Ltd. 490000 4729.48 8.39 NAV Divi Laboratories Ltd. 104500 4606.62 8.17 Direct - IDCW : 18.8359 Ltd. 111365 3562.96 6.32 Direct - Growth : 18.8359 Regular - IDCW : 17.2065 Ltd. 125426 2541.63 4.51 Regular - Growth : 17.2065 J.B.Chemicals & Pharmaceuticals Ltd. 103000 1715.16 3.04 FUND SIZE Procter & Gamble Health Ltd. 26000 1442.92 2.56 Rs. 563.54 (Rs. in Cr.) Lupin Ltd. 123000 1413.39 2.51 MONTHLY AVERAGE AUM Ltd. 186000 1200.07 2.13 Rs. 548.40 (Rs. in Cr.) Indoco Remedies Ltd. 279000 1151.43 2.04 TURN OVER Ltd. 53087 1140.68 2.02 Portfolio Turnover (Total) 41.47% Portfolio Turnover (Equity component only) 41.47%

EXPENSE RATIO** Direct 1.11 SIP - If you had invested INR 10000 every month Regular 2.61 **Note: The rates specified are actual month end expenses charged 1 Year 3 Year 5 Year 7 Year 10 Year Since Inception as on Jun 30, 2021. The above ratio includes the Service tax on Investment Management Fees. The above ratio excludes, proportionate charge (out of maximum 30 bps on daily average net Total Amount Invested (Rs.) 120,000 360,000 600,000 NA NA 660,000 assets allowed) in respect sales beyond T-30 cities assets, wherever applicable. Total Value as on Jun 30, 2021 (Rs.) 148,023 600,581 1,065,994 NA NA 1,172,919 VOLATILITY MEASURES^ FUND BENCHMARK Returns 46.31% 36.31% 23.21% NA NA 20.93% Std. Dev (Annualised) 19.09 25.41 Total Value of B: Nifty Pharma TRI 144,070 548,014 905,459 NA NA 983,630 Sharpe Ratio 0.33 0.17 B: Nifty Pharma TRI 39.47% 29.35% 16.49% NA NA 14.45% Portfolio Beta 0.70 1.00 R Squared 0.87 1.00 Total Value of AB: Nifty 50 TRI 147,862 500,192 920,102 NA NA 1,050,882 Treynor 2.60 1.27 AB: Nifty 50 TRI 46.03% 22.62% 17.15% NA NA 16.87% Jenson 0.93 NA ^Risk-free rate based on the FBIL Overnight MIBOR rate of 3.36% as (Inception date :28-Dec-2015) (First Installment date : 01-Jan-2016) on Jun 30, 2021 Past performance may or may not be sustained in the future. Returns greater than 1 year period are compounded annualized. Income Distribution cum capital For calculation methodology please refer to Pg 68 withdrawals are assumed to be reinvested and bonus is adjusted. Load is not taken in to consideration. For SIP returns, monthly investment of equal amounts invested MINIMUM INVESTMENT / on the 1st day of every month has been considered. MULTIPLES FOR NEW INVESTMENT For scheme performance refer pages 52 - 68. *B: Benchmark, AB: Additional Benchmark Rs. 5,000/- and in multiples of Re. 1/- thereafter. Source: MFI Explorer ADDITIONAL INVESTMENT/ MULTIPLES FOR EXISTING INVESTORS Rs. 1,000/- and in multiples of Re. 1/- thereafter. Top 10 Holdings Equity Sector Allocation LOAD STRUCTURE Issuer Name % to NAV Sun Pharmaceutical Industries Ltd. 9.47 Entry Load : Not Applicable Dr. Reddys Labaratories Ltd. 9.24 Pharma 77.14% Exit Load : 0.25% of NAV if redeemed/switched out before 30 Cipla Ltd. 8.62 days from the date of allotment. Aurobindo Pharma Ltd. 8.39 Divi Laboratories Ltd. 8.17 Please refer to our Tata Mutual Fund website for fundamental changes, wherever applicable Alkem Laboratories Ltd. 6.32 Enterprise Ltd. 4.53 Healthcare Services 20.79% Ipca Labs 4.51 Fortis Healthcare Ltd. 3.43 J.b.chemicals & Pharmaceuticals Ltd. 3.04 Total 65.72 0.00% 16.00% 32.00% 48.00% 64.00% 80.00% 96.00%

Market Capitalisation wise Exposure NAV Movement

Large Cap 55.43% Tata India Pharma And Healthcare Fund - Reg - Growth Nifty Pharma TRI 210 Mid Cap 27.07% 182 154 Small Cap 17.50% 126 98

Market Capitalisation is as per list provided by AMFI. 70 Jun-18 Jun-19 Jun-20 Jun-21 www.tatamutualfund.com Mutual Fund investments are subject to market risks, read all scheme related documents carefully TATA MUTUAL FUND 25